{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:04:06Z","timestamp":1791216246713,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1067\/mjd.2000.108321","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T00:17:12Z","timestamp":1027556232000},"page":"S31-S35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"P3","title":["Pharmacokinetics and safety of tazarotene"],"prefix":"10.1067","volume":"43","author":[{"given":"Alan","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1067\/mjd.2000.108321_bib1","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0190-9622(98)70309-3","article-title":"The pathogenesis of psoriasis and the mechanism of action of tazarotene","volume":"39","author":"Duvic","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0190-9622(97)70216-0","article-title":"Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect","volume":"37","author":"Weinstein","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0190-9622(98)70594-8","article-title":"Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis","volume":"38","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0190-9622(98)70008-8","article-title":"Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1517\/13543784.6.10.1537","article-title":"Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis","volume":"6","author":"Duvic","year":"1997","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1067\/mjd.2000.108321_bib6","first-page":"133","article-title":"Tazarotene, a receptor-selective topical retinoid, in the treatment of psoriasis","volume":"17","author":"Guenther","year":"1999","journal-title":"Today Ther Trends"},{"key":"10.1067\/mjd.2000.108321_bib7","first-page":"349","article-title":"Tazarotene gel is safe and effective in the treatment of acne vulgaris","volume":"63","author":"Shalita","year":"1999","journal-title":"Cutis"},{"issue":"2S","key":"10.1067\/mjd.2000.108321_bib8","first-page":"1","article-title":"Topical retinoids in the treatment of acne vulgaris","volume":"64","author":"Bershad","year":"1999","journal-title":"Cutis"},{"key":"10.1067\/mjd.2000.108321_bib9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003088-199937040-00001","article-title":"Clinical pharmacokinetics and drug metabolism of tazarotene","volume":"37","author":"Tang-Liu DD-S","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1067\/mjd.2000.108321_bib10","first-page":"650","article-title":"Percutaneous absorption of AGN 190168 0.1 gel, a new synthetic retinoid, through human skin in vivo [abstract]","volume":"98","author":"Franz","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"suppl","key":"10.1067\/mjd.2000.108321_bib11","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/S0190-9622(98)70310-X","article-title":"Pharmacokinetics and safety review of tazarotene","volume":"39","author":"Marks","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib12","doi-asserted-by":"crossref","unstructured":"NDA 20-600. Approved June 13, 1997.","DOI":"10.1016\/S0899-9007(97)90410-X"},{"issue":"suppl","key":"10.1067\/mjd.2000.108321_bib13","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0190-9622(97)80395-7","article-title":"Tazarotene: the first receptor-selective topical retinoid for the treatment of plaque psoriasis","volume":"37","author":"Chandraratna","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199912023412312","article-title":"Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma","volume":"341","author":"Peris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2000.108321_bib15","unstructured":"Yu Z, Matsumoto RM, Sefton J, Lew-Kaya D, Kopper S, Walker PS, et al. Pharmacokinetics of tazarotene in female patients with facial acne following facial application of 0.1% tazarotene gel for 28 days. Poster presented at the 58th Annual Meeting of the American Academy of Dermatology, March 10-15, 2000, San Francisco, CA."},{"key":"10.1067\/mjd.2000.108321_bib16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0022-2275(20)42615-X","article-title":"Identification and quantitation of all-trans - and 13-cis -retinoic acid and 13-cis -4-oxoretinoic acid in human plasma","volume":"31","author":"Eckhoff","year":"1990","journal-title":"J Lipid Res"},{"issue":"suppl","key":"10.1067\/mjd.2000.108321_bib17","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0190-9622(97)70059-8","article-title":"The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use","volume":"36","author":"Latriano","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.108321_bib18","unstructured":"Data on file, Allergan Inc. Study 022."},{"key":"10.1067\/mjd.2000.108321_bib19","series-title":"Physicians\u2019 Desk Reference","first-page":"502","year":"2000"},{"key":"10.1067\/mjd.2000.108321_bib20","series-title":"Tazorac\u00ae patient package insert","year":"1997"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200610277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200610277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:22:35Z","timestamp":1759267355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962200610277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["S0190962200610277"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2000.108321","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety of tazarotene","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1067\/mjd.2000.108321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}